Cargando…

Plasma Level of MMP-10 May Be a Prognostic Marker in Early Stages of Breast Cancer

Background: Stromelysins are potential breast cancer biomarkers. The aim of the study was to evaluate if plasma levels of selected metalloproteinases (MMPs) (stromelysin-1 (MMP-3) and stromelysin-10 (MMP-10)) and cancer antigen 15-3 (CA 15-3) used separately and in combination demonstrated diagnosti...

Descripción completa

Detalles Bibliográficos
Autores principales: Piskór, Barbara Maria, Przylipiak, Andrzej, Dąbrowska, Emilia, Sidorkiewicz, Iwona, Niczyporuk, Marek, Szmitkowski, Maciej, Ławicki, Sławomir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7767367/
https://www.ncbi.nlm.nih.gov/pubmed/33371324
http://dx.doi.org/10.3390/jcm9124122
_version_ 1783628942009171968
author Piskór, Barbara Maria
Przylipiak, Andrzej
Dąbrowska, Emilia
Sidorkiewicz, Iwona
Niczyporuk, Marek
Szmitkowski, Maciej
Ławicki, Sławomir
author_facet Piskór, Barbara Maria
Przylipiak, Andrzej
Dąbrowska, Emilia
Sidorkiewicz, Iwona
Niczyporuk, Marek
Szmitkowski, Maciej
Ławicki, Sławomir
author_sort Piskór, Barbara Maria
collection PubMed
description Background: Stromelysins are potential breast cancer biomarkers. The aim of the study was to evaluate if plasma levels of selected metalloproteinases (MMPs) (stromelysin-1 (MMP-3) and stromelysin-10 (MMP-10)) and cancer antigen 15-3 (CA 15-3) used separately and in combination demonstrated diagnostic usefulness in breast cancer (BC). Methods: The study group consisted of 120 patients with BC, while the control group included 40 patients with benign breast cancer and 40 healthy individuals. Concentrations of MMP-3 and MMP-10 were determined by enzyme-linked immunosorbent assay; CA 15-3 was determined by chemiluminescent microparticle immunoassay. Results: In the group of patients with BC, the area under the curve (AUC) was significantly higher for all markers (except MMP-3) and all sets of markers. At the earliest disease stage, only MMP-10 had a significantly higher AUC (AUC = 0.8692, p < 0.001). Moreover, MMP-10 had the highest AUC (0.9166) among parameters tested separately. The highest AUC was observed for the combination of MMP-10 + CA 15-3 and MMP-3 + MMP-10 + CA 15-3 in line with disease progression (stage I 0.8884 and 0.8906, stage II 0.9244 and 0.9308, stages III + IV 0.9919 and 0.9944, respectively, p < 0.001 in all cases). Conclusions: The results suggest that MMP-10 could be a potential marker in early stages of BC. Moreover, plasma concentration of MMP-10 and MMP-3 in combination with CA 15-3 may improve diagnosis of this type of cancer.
format Online
Article
Text
id pubmed-7767367
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77673672020-12-28 Plasma Level of MMP-10 May Be a Prognostic Marker in Early Stages of Breast Cancer Piskór, Barbara Maria Przylipiak, Andrzej Dąbrowska, Emilia Sidorkiewicz, Iwona Niczyporuk, Marek Szmitkowski, Maciej Ławicki, Sławomir J Clin Med Article Background: Stromelysins are potential breast cancer biomarkers. The aim of the study was to evaluate if plasma levels of selected metalloproteinases (MMPs) (stromelysin-1 (MMP-3) and stromelysin-10 (MMP-10)) and cancer antigen 15-3 (CA 15-3) used separately and in combination demonstrated diagnostic usefulness in breast cancer (BC). Methods: The study group consisted of 120 patients with BC, while the control group included 40 patients with benign breast cancer and 40 healthy individuals. Concentrations of MMP-3 and MMP-10 were determined by enzyme-linked immunosorbent assay; CA 15-3 was determined by chemiluminescent microparticle immunoassay. Results: In the group of patients with BC, the area under the curve (AUC) was significantly higher for all markers (except MMP-3) and all sets of markers. At the earliest disease stage, only MMP-10 had a significantly higher AUC (AUC = 0.8692, p < 0.001). Moreover, MMP-10 had the highest AUC (0.9166) among parameters tested separately. The highest AUC was observed for the combination of MMP-10 + CA 15-3 and MMP-3 + MMP-10 + CA 15-3 in line with disease progression (stage I 0.8884 and 0.8906, stage II 0.9244 and 0.9308, stages III + IV 0.9919 and 0.9944, respectively, p < 0.001 in all cases). Conclusions: The results suggest that MMP-10 could be a potential marker in early stages of BC. Moreover, plasma concentration of MMP-10 and MMP-3 in combination with CA 15-3 may improve diagnosis of this type of cancer. MDPI 2020-12-21 /pmc/articles/PMC7767367/ /pubmed/33371324 http://dx.doi.org/10.3390/jcm9124122 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Piskór, Barbara Maria
Przylipiak, Andrzej
Dąbrowska, Emilia
Sidorkiewicz, Iwona
Niczyporuk, Marek
Szmitkowski, Maciej
Ławicki, Sławomir
Plasma Level of MMP-10 May Be a Prognostic Marker in Early Stages of Breast Cancer
title Plasma Level of MMP-10 May Be a Prognostic Marker in Early Stages of Breast Cancer
title_full Plasma Level of MMP-10 May Be a Prognostic Marker in Early Stages of Breast Cancer
title_fullStr Plasma Level of MMP-10 May Be a Prognostic Marker in Early Stages of Breast Cancer
title_full_unstemmed Plasma Level of MMP-10 May Be a Prognostic Marker in Early Stages of Breast Cancer
title_short Plasma Level of MMP-10 May Be a Prognostic Marker in Early Stages of Breast Cancer
title_sort plasma level of mmp-10 may be a prognostic marker in early stages of breast cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7767367/
https://www.ncbi.nlm.nih.gov/pubmed/33371324
http://dx.doi.org/10.3390/jcm9124122
work_keys_str_mv AT piskorbarbaramaria plasmalevelofmmp10maybeaprognosticmarkerinearlystagesofbreastcancer
AT przylipiakandrzej plasmalevelofmmp10maybeaprognosticmarkerinearlystagesofbreastcancer
AT dabrowskaemilia plasmalevelofmmp10maybeaprognosticmarkerinearlystagesofbreastcancer
AT sidorkiewicziwona plasmalevelofmmp10maybeaprognosticmarkerinearlystagesofbreastcancer
AT niczyporukmarek plasmalevelofmmp10maybeaprognosticmarkerinearlystagesofbreastcancer
AT szmitkowskimaciej plasmalevelofmmp10maybeaprognosticmarkerinearlystagesofbreastcancer
AT ławickisławomir plasmalevelofmmp10maybeaprognosticmarkerinearlystagesofbreastcancer